Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA Breakthrough Device-designated AI platform predicting sepsis mortality risk in emergency departments; $17.08M from Breyer Capital and YC generating $2.6M revenue at 13-person Burlington-based team.
Biocogniv is a Burlington, Vermont-based clinical AI company that has developed an FDA Breakthrough Device Designation-granted platform for predicting sepsis-related mortality and ICU admission risk in emergency departments — using AI analysis of routine clinical data (vital signs, lab values, patient history) to identify patients at highest risk of deterioration hours before clinical signs become obvious to clinicians, enabling earlier intervention in one of healthcare's most time-sensitive conditions. Founded in 2019 and a Y Combinator W20 graduate, Biocogniv raised $17.08 million from Breyer Capital and YC, generating $2.6 million in revenue in 2024 with a 13-person team.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.